Semaglutide for Weight Loss
The original GLP-1 agonist that started the revolution. FDA-approved as Ozempic (diabetes) and Wegovy (obesity). Generic research semaglutide is the most affordable option in Vietnam.
Education only: This page describes what clinical trials and the FDA-approved labeling report. It is not medical advice and not a dosing protocol. Dose selection and any change to a regimen are decisions for a licensed prescriber. Nothing here tells you to start, stop, or adjust a dose.
15%
Avg Weight Loss
68 weeks
Trial Duration
Weekly
Frequency
FDA Approved
Status
Ozempic vs Generic Semaglutide
| Brand Ozempic | Generic Semaglutide | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Mechanism | Identical | Identical |
| Form | Pre-filled injection pen | Vial + syringe |
| Price (monthly) | ~$800 to 1200 USD | ~$50 to 150 USD |
| COA available | Pharmaceutical grade | Requires verification |
| Availability Vietnam | Limited / very expensive | Available via suppliers |
Bottom line: The active molecule is identical. Generic research semaglutide from a verified supplier with COA is chemically equivalent to Ozempic. The price difference is entirely pharmaceutical markup, not quality. Always verify COA.
Why the Approved Label Starts Low
The FDA-approved labelling for semaglutide (Ozempic and Wegovy) does not start at the full dose. It begins low and steps up in stages, and the reason given is tolerance: the gastrointestinal side effects cluster in the first weeks and during each increase, so the label holds the opening dose for a period before any change.
This page does not reproduce the figures or the pace. Those live in the prescribing information, and which dose a person is on, how fast it moves, and whether it moves at all are decisions a licensed prescriber makes after assessing them. A schedule copied off a guide is not a substitute for that.
Educational summary of what the approved labelling describes, not a personal protocol and not a recommendation.
Who Should Choose Semaglutide?
What to Expect
The opening weeks are about tolerance rather than weight loss. Mild appetite changes. Some first-week nausea is common.
Clear appetite suppression for most people. Many users report 2 to 4kg lost from reduced food intake alone.
Consistent weekly weight loss. Energy often improves. Body composition noticeably changing.
Weight loss approaches the 15% clinical average. Plateau management becomes important.
Comparing research-grade GLP-1 options? See how semaglutide stacks up against the wider field, ranked by trial effect size, at Peptara Labs, then verify any supplier against a COA.